SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Apr 22, 2015
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: April 22, 2015 · CIK: 0001607678 · Accession: 0001193125-15-142222
AI Filing Summary & Sentiment
File numbers found in text: 333-197182
Letter
Acceleration Request
LAIDLAW & COMPANY (UK) LTD.
546 Fifth Avenue, 5th Floor
New York, New York 10036
April 22, 2015
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey Riedler, Assistant Director
Re: Viking Therapeutics, Inc. (the “Company”)
File No. 333-197182
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), we, the representative of the several underwriters (the “Representative”), hereby join in the request of the Company that the effective time of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:30p.m. Eastern Time on April 28, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that through the date hereof, the preliminary prospectus, dated April 9, 2015 and the preliminary prospectus, dated April 22, 2015, was distributed approximately as follows:
Sent to Underwriters:
Sent to Dealers:
Sent to Institutional Investors:
Sent to Others:
Total:
1,353
The Representative confirms on behalf of itself and the several underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 promulgated under of the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
LAIDLAW & COMPANY (UK) LTD.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request LAIDLAW & COMPANY (UK) LTD. 546 Fifth Avenue, 5th Floor New York, New York 10036 April 22, 2015 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: Viking Therapeutics, Inc. (the “Company”) File No. 333-197182 Registration Statement on Form S-1 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), we, the representative of the several underwriters (the “Representative”), hereby join in the request of the Company that the effective time of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:30p.m. Eastern Time on April 28, 2015, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that through the date hereof, the preliminary prospectus, dated April 9, 2015 and the preliminary prospectus, dated April 22, 2015, was distributed approximately as follows: Sent to Underwriters: 2 Sent to Dealers: 1 Sent to Institutional Investors: 375 Sent to Others: 975 Total: 1,353 The Representative confirms on behalf of itself and the several underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 promulgated under of the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. Very truly yours, LAIDLAW & COMPANY (UK) LTD. as representative of the underwriters By: /s/ Hugh Regan Name: Hugh Regan Title: Executive Director